Positive Interim ResultsAC Immune announced positive additional interim and safety data from the Phase 2 VacSYn trial for ACI-7104, showing significant increases in anti-alpha-syn antibodies.
Potential Financial BoostIf Takeda exercises the option, AC Immune receives a $200M-$400M exercise fee.
Vaccine Safety And EfficacyThe ongoing P1b/2 ABATE study of ACI-24.060 reports promising safety profile results, which could make the approach best in class.